2. What does the future hold after a failed merger?

If at first you don’t succeed, you could keep trying, or you could get back to the basics of what you do well. That is the plan for Allergan after the failed merger with Pfizer earlier this year. According to an article from Business Insider, the company has shaken off the setback and plans to move forward focusing on their best-selling Botox, a new “flagship” product in their women’s health program, and other drugs currently in development. Allergan’s CEO, Brent Saunders, made a point to distinguish the company as a “growth pharma” company and said, “It’s our commitment to doing what [we] do best, which is introduce novel compounds to the healthcare community.”